Mutated p53 gene is an independent adverse predictor of survival in colon carcinoma

Archives of Surgery

Volumn 132, Issue 4, 1997, Pages 371-375

  Pricolo, Victor E ^a,b   Finkelstein, Sydney D ^a   Hansen, Katrine ^a   Cole, Bernard F ^a   Bland, Kirby I ^a  

^a BROWN UNIVERSITY   (United States)

^b RHODE ISLAND HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ADULT; AGED; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; COLON CARCINOMA; CONFERENCE PAPER; FEMALE; GENE LOCATION; GENE MUTATION; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MOLECULAR GENETICS; PREDICTION; PRIORITY JOURNAL; SURVIVAL TIME;

EID: 0030934802     PISSN: 00040010     EISSN: None     Source Type: Journal    
DOI: 10.1001/archsurg.1997.01430280045006     Document Type: Conference Paper

References (30)

1. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal tumor development. N Engl J Med. 1988;319:525-532.
2. Weinberg R. Oncogenes, antioncogenes and the molecular bases of multistep carcinogenesis. Cancer Res. 1989;49:3713-3741.
3. Fearon ER. Molecular genetics of the adenoma-carcinoma sequence. Adv Intern Med. 1994;39:123-147.
4. Laurent-Puig P, Olschwang S, Delattre O, et al. Survival and acquired genetic alterations in colorectal cancer. Gastroenterology. 1992;102:1136-1141.
5. Williams A, Browne S, Manning A, van der Stappen JW, Parsheva C. Biological consequences of the genetic changes which occur during human colorectal carcinogenesis. Semin Cancer Biol. 1993;4:153-159.
6. Finkelstein SD, Sayegh R, Bakker A, Swalsky PA. Determination of tumor aggressiveness in colorectal cancer by K-ras-2 analysis. Arch Surg. 1993;128: 526-532.
7. Pricolo VE, Finkelstein SD, Wu TT, et al. Prognostic value of TP53 and K-ras-2 mutational analysis in stage III carcinoma of the colon. Am J Surg. 1996;171: 41-46.
8. Hamilton SR. Molecular genetics of colorectal carcinoma. Cancer. 1992;70:1216-1221.
9. Koorey DJ, McCaughan GW. Tumor suppressor genes and colorectal neoplasia. J Gastroenterol Hepatol. 1993;8:174-184.
10. Kinzler K, Nilbert M, Su L, et al. Identification of FAP locus genes from chromosome 5q21. Science. 1991;253:661-665.
11. Nakamura Y. The role of adenomatous polyposis coli APC gene in human cancers. Adv Cancer Res. 1993;62:65-87.
12. Lynch H, Smyrk T, Watson P, et al. Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an updated review. Gastroenterology. 1993;104:1535-1549.
13. Fisnel R, Lescoe K, Rao M, et al. The human mutator gene homolog HMS2 and its association with hereditary nonpolyposis colon cancer. Cell. 1993;75: 1027-1038.
14. Muschel RJ, McKenna WG. Oncogenes and tumor progression. Cancer Res. 1989;9:1395-1406.
15. Weiner T, Cance WG. Molecular mechanisms involved in tumorigenesis and their surgical implications. Am J Surg. 1994;167:428-434.
16. Bell SM, Scott N, Cross D, et al. Prognostic value of p53 overexpression and c-Ki-ras gene mutations in colorectal cancer. Gastroenterology. 1993;104;57-64.
17. Jen J, Kim H, Piantadosi S, et al. Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med. 1994;331:213-221.
18. Harris CG, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med. 1993;329:1318-1327.
19. Carder PJ, Cripps KJ, Morris R, et al. Br J Cancer. 1995;71:215-218.
20. Lothe RA, Fossil T, Danielsen HE, et al. Molecular genetic studies of tumor suppressor gene regions on chromosomes 13 and 17 in colorectal tumors. J Natl Cancer Inst. 1992;84:1100-1108.
21. Goh HS, Chan CS, Khine K, Smith DR. p53 And behaviour of colorectal cancer. Lancet. 1994;344:233-234.
22. Ookawa K, Sakamoto M, Hirohashi S, et al. Concordant p53 and DCC alterations and allelic losses on chromosomes 13 and 14q associated with liver metastases of colorectal carcinoma. Int J Cancer. 1993;53:382-387.
23. Meling GI, Lothe RA, Brresen AL, et al. The TP53 tumour suppressor gene in colorectal carcinomas: genetic alterations on chromosome 17. Br J Cancer. 1993;67:88-92.
24. Remvikos Y, Tominafa O, Hammel P, et al. Increased p53 protein content of colorectal tumours correlates with poor survival. Br J Cancer. 1992;66:758-764.
25. Zeng ZS, Sarkis AS, Zhang ZF, et al. p53 Nuclear overexpression: an independent predictor of survival in lymph node-positive tal cancer patients, J Clin Oncol. 1994;12:2043-2050.
26. Sun XF, Carstensen JM, Zhang H, et al. Prognostic significance of cytoplasmic p53 oncoprotein in colorectal adenocarcinoma. Lancet. 1992;340:1369-1373.
27. Dix B, Robbins P, Carrello S, House A, lacopetta B. Comparison of p53 gene mutation and protein overexpression in colorectal carcinomas. Br J Cancer. 1994;70:585-590.
28. Pricolo VE, Finkelstein SD, Bland KI. Topographic genotyping of colorectal carcinoma: from molecular carcinogenesis models to clinical relevance. Ann Surg Oncol. In press.
29. Yin J, Harpaz N, Tong Y, et al. p53 Point mutations in dysplastic and cancerous ulcerative colitis lesions. Gastroenterology. 1993;104:1633-1639.
30. Tominaga O, Hamelin R, Trouvat V, et al. Frequently elevated content of immunochemically defined wild-type p53 protein in colorectal adenomas. Oncogene. 1993;8:2653-2658.